Under the settlement, AbbVie will allow Boehringer to launch its FDA-approved Humira biosimilar in July 2023. The deal gives Boehringer nonexclusive intellectual property license to sell its copycat version, Cyltezo, in exchange for royalty payments to AbbVie.
The financial terms of the deal weren’t disclosed.
Humira, used to treat diseases ranging from rheumatoid arthritis to gut disorders, was the world’s best-selling drug in 2018, with nearly $19 million in global sales.
The initial patent for Humira expired in December 2016, but AbbVie secured more than 100 additional patents for the drug. In 2017, AbbVie sued Boehringer, claiming that Cyltezo would infringe on many of those patents.
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
